Clinical toxicology of newer recreational drugs
Clinical Toxicology October 1, 2011 DOI: 10.3109/15563650.2011.615318 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Clinical toxicology Recreational drug Pharmacology Intensive care medicine |
| Citations | 289 |
| Key findings | Management of acute toxicity from emerging recreational drugs is pragmatic and largely extrapolated from experience with established stimulant or hallucinogenic drugs. |
Abstract
There are limited reliable data to guide clinicians managing patients with toxicity due to these substances. The harms associated with emerging recreational drugs are not fully documented, although it is clear that they are not without risk. Management of users with acute toxic effects is pragmatic and primarily extrapolated from experience with longer established stimulant or hallucinogenic drugs such as amfetamines, 3,4-methylenedioxymethamfetamine (MDMA) and lysergic acid diethylamide (LSD).